The use of simulation-based sensitivity analyses is fundamental for evaluating and comparing candidate designs of future clinical trials. In this context, sensitivity analyses are especially useful to
Adaptive two-stage design with treatment selection, also called seamless Phase II/III design, has been recognized to save sample size and time to enhance the development of effective treatments. These
Traditional phase I dose finding cancer clinical trial designs aim to determine the maximum tolerated dose (MTD) of the investigational cytotoxic agent based on a single toxicity outcome, assuming a m
Breast cancer screening is effective in reducing mortality from the disease. However, the sensitivity of mammography is not optimal, which limits the effectiveness of screening, particularly in younge
